An underfilled blood collection tube contains too much anticoagulant relative to the blood collected. The additive amount is set during manufacture; it does not decrease when collection stops early. This imbalance can alter the specimen before analysis, even when the tube looks clean, contains no visible clot, and provides enough volume for the instrument.
The most consequential example is a sodium citrate tube used for coagulation testing. Its intended ratio is nine parts blood to one part citrate solution. Underfilling increases the citrate available to bind calcium, which can produce falsely prolonged clotting times. EDTA and heparin tubes also have fill requirements, but their risks and acceptance limits are different. A fill rule established for citrate should not automatically be applied to every anticoagulant tube.
Blood collection tubes contain a specified quantity of anticoagulant matched to their intended draw volume. Depending on the tube, the additive may be a liquid, a spray-dried coating, or another dried preparation. With a liquid additive, underfilling can cause both excess anticoagulant exposure and greater specimen dilution. With a dried additive, there is no comparable liquid dilution, but the anticoagulant concentration per milliliter of blood still increases.
The relationship is straightforward: if the amount of additive remains constant, collecting less blood increases the additive-to-blood ratio. A tube filled to 80% of its intended blood volume exposes each milliliter of blood to 25% more additive than intended. This calculation describes the ratio change—not the percentage error in a laboratory result. Analytical effects depend on the additive, test method, specimen characteristics, and degree of underfilling.
Consider a citrate tube designed to collect 2.7 mL of blood into 0.3 mL of citrate solution:
These figures also explain why the amount of empty space above the specimen is not a reliable acceptance criterion. Tube dimensions, additive volume, and nominal draw volume vary. The correct reference is the manufacturer’s fill indicator or specified draw volume, not how full the tube appears compared with another product.

Sodium citrate prevents clotting by binding calcium. During many coagulation assays, the analyzer adds calcium back under controlled conditions so that clot formation can be measured. The test system assumes that specimen preparation has maintained the specified blood-to-citrate ratio.
When too little blood is collected, excess citrate can bind more of the calcium added during testing. Liquid citrate also dilutes the plasma more than intended. These effects can interfere with the assay’s reaction conditions and produce an apparent coagulation abnormality that originates in collection rather than in the patient.
Prothrombin time (PT), its derived international normalized ratio (INR), and activated partial thromboplastin time (aPTT) can be affected. The magnitude of the effect is not identical across reagents or instruments, and aPTT may be particularly sensitive in some testing systems. Other citrate-based assays have their own susceptibility. A result cannot be corrected reliably by applying a simple multiplier based on the missing blood volume.
This distinction matters when interpreting a prolonged result. Genuine anticoagulant treatment, a coagulation-factor deficiency, and an underfilled specimen can all contribute to abnormal clotting times. The laboratory should not dismiss a result solely because underfilling is suspected, but it should resolve specimen suitability before using that result to support treatment decisions.
A commonly used criterion for routine citrate coagulation specimens is collection to at least 90% of the intended draw volume. This is a specimen-acceptance convention, not proof that every assay is unaffected at that level. The applicable limit should come from the tube manufacturer’s instructions and the laboratory’s validated policy for the requested tests.
CLSI guidance on venous blood collection and coagulation specimen handling provides an established framework for collection and processing. Manufacturer instructions define product-specific requirements. Neither should be replaced by a generic assumption that “there is enough plasma to run the test.” Sufficient analytical volume and an acceptable anticoagulant ratio are separate requirements.
A laboratory may have evidence supporting a particular tolerance for a defined tube-and-assay combination. That evidence should not be transferred to another citrate concentration, tube design, reagent, or specialized assay without assessment. Tubes containing 3.2% and 3.8% sodium citrate are not automatically interchangeable within a validated testing system.
High hematocrit creates a related but distinct problem. Citrate is added in proportion to whole-blood volume, while coagulation testing is performed on plasma. When red cells occupy an unusually large fraction of the specimen, less plasma is available to interact with the fixed citrate amount.
Consequently, a tube filled exactly to its mark can still contain excessive citrate relative to plasma. For hematocrit values above 55%, established coagulation guidance calls for citrate-volume adjustment using an approved procedure. The laboratory should calculate and coordinate that adjustment before collection.
Underfilling a standard tube is not a substitute for hematocrit adjustment. It reduces the blood volume while leaving the citrate quantity unchanged, worsening rather than correcting the imbalance. Similarly, removing citrate informally introduces volume and handling uncertainty. A specially prepared, documented collection procedure is necessary when adjustment is indicated.
EDTA also binds calcium, but it is principally used to preserve whole blood for hematology testing rather than to support a controlled recalcification reaction. Underfilling increases EDTA exposure per unit of blood. Excess EDTA can alter cell volume and morphology, potentially affecting red-cell indices and blood-film interpretation. The effect depends on the EDTA formulation, degree of underfilling, storage conditions, and time before analysis.
Liquid EDTA formulations can introduce additional dilution when the blood volume is low. Dried EDTA formulations avoid that particular dilution mechanism, but they do not eliminate ratio-related concerns. An analyzer’s ability to aspirate a small specimen therefore does not establish that the specimen has acceptable cell preservation.
For heparin tubes, underfilling likewise increases the amount of anticoagulant relative to blood. Its significance depends strongly on the requested analyte and heparin formulation. There is no single universal fill threshold that can be assumed to protect every chemistry test.
Blood-gas collection illustrates the risk particularly clearly. Excess liquid heparin can dilute a specimen, while heparin can also bind cations and affect ionized calcium measurement. Purpose-designed dry, electrolyte-balanced heparin collection devices reduce some of these problems, but still require collection within their specified volume range.
The practical distinction is that citrate underfilling directly disrupts a carefully controlled coagulation-testing ratio. EDTA and heparin underfilling creates different preservation or analytical risks. Each requires a tube-specific and test-specific acceptance decision—not a universal rule based on cap color or minimum instrument volume.
Early flow cessation can result from loss of venous access, a collapsing vein, obstruction, compromised tube vacuum, or removal of the tube before filling finishes. An expired or damaged evacuated tube may not draw its intended volume. The observed short draw should prompt a check of the collection conditions rather than an assumption that the tube was designed for less blood.
Winged collection sets create a specific issue when a citrate tube is collected first. Air in the tubing enters the evacuated tube before blood reaches it, consuming part of the available draw capacity. Where required by the collection procedure, a discard tube is used to fill the tubing before collecting the citrate specimen. The discard volume should be sufficient for the tubing’s dead space; it is not an arbitrary extra blood draw.
Collection from vascular access devices introduces another risk: contamination with flush solution or residual heparin. Such contamination may coexist with underfilling but is not the same problem. A correctly filled citrate tube can still be unsuitable if line-collection requirements were not followed.
When a patient has limited obtainable blood volume, an approved low-draw tube is preferable to deliberately underfilling a standard tube. The smaller tube contains an additive quantity matched to its intended draw. A small external tube size alone does not establish suitability; the additive, required volume, and intended tests must be confirmed.
Check the fill level against the specific tube’s indicator or nominal draw, then apply the laboratory’s acceptance policy for the requested tests. For citrate specimens outside the permitted range, recollection is generally the appropriate action. If recollection is difficult or urgent testing is required, the testing laboratory should decide whether any analysis is supportable and how limitations must be communicated.
Several attempted remedies create additional problems:
Mixing remains essential. Follow the manufacturer’s specified gentle-inversion procedure promptly after collection; vigorous shaking can damage the specimen. A properly filled but inadequately mixed tube may contain clots or microclots. Conversely, an underfilled tube may remain visibly clot-free while still producing misleading results. Absence of a clot is not evidence of a correct anticoagulant ratio.
Record a rejected specimen as underfilled rather than merely “insufficient.” The distinction helps separate an incorrect blood-to-additive ratio from inadequate volume for aspiration or repeat testing. Recurrent short draws should be reviewed against tube type, collection equipment, and collection technique.
The decisive question is not whether the instrument can test the sample. It is whether the blood was collected under the conditions the method requires. Correct fill, appropriate additive, effective mixing, and any necessary hematocrit adjustment establish those conditions; none can be inferred from specimen volume alone.
Related Posts
Online Message
PROFESSIONAL CONSULTATION
If you are interested in our products and want to know more details, please leave a message here, we will reply you as soon as we can.